FDA Expands Anktiva Approval for BCG-Unresponsive High-Grade Papillary Bladder Cancer

1-Minute Summary

The US Food and Drug Administration (FDA) expanded the approved use of nogapendekin alfa inbakicept-pmln (Anktiva; ImmunityBio/Altor BioScience) in combination with Bacillus Calmette-Guérin (BCG) for adults with high-grade papillary-only non–muscle-invasive bladder cancer that has not responded adequately to previous BCG treatment.

According to the October 14, 2026, report from Healio, the expanded indication addresses a group of patients whose cancer remains confined to the bladder’s non–muscle-invasive layers and who have high-grade papillary tumors without carcinoma in situ. The report describes Anktiva as the first treatment specifically approved for this setting.

Anktiva is an interleukin-15 receptor agonist administered directly into the bladder through a catheter and used alongside BCG. The expanded indication was supported by evidence from patients with carcinoma in situ, together with the FDA’s assessment of similarities between carcinoma in situ and high-grade papillary-only disease, including the risk of recurrence or progression after BCG treatment fails.

The reported treatment schedule begins with weekly administration for 6 weeks, with subsequent treatment decisions guided by cancer response. Potential adverse effects include urinary symptoms, hematuria, urinary tract infections, fever, chills, musculoskeletal pain, and elevated potassium and creatinine levels.

Why This Matters

BCG is a standard initial treatment for high-risk non–muscle-invasive bladder cancer. Although many patients benefit, some experience persistent or recurrent disease despite treatment. These patients may face ongoing risks of recurrence and progression, making additional treatment options important.

The FDA’s expanded approval provides a specifically indicated option for adults with BCG-unresponsive, high-grade papillary-only disease. This is clinically relevant because papillary-only tumors and carcinoma in situ are distinct presentations of bladder cancer, even though both can carry substantial risks when BCG treatment is no longer effective.

Anktiva is an interleukin-15 receptor agonist intended to enhance immune activity. It is used with BCG rather than as a replacement for BCG in the approved combination regimen.

The decision also illustrates how regulatory authorities may extend treatment indications when available evidence and disease-specific considerations support a new use. However, the supplied report does not provide numerical response rates, comparative efficacy estimates, or detailed safety results specifically for the newly approved subgroup.

Regulatory Update at a Glance

What the FDA Said

R. Angelo de Claro, MD, director of the FDA’s Oncology Center of Excellence, described the agency’s approach to the expanded indication:

“We listen to patients, clinicians and researchers, and we act when the science supports a new approach.”

He continued:

“For Anktiva, our review of the similarities between these cancers allowed us to build on the results in patients with [carcinoma in situ] and expand treatment options for people with high-grade papillary tumors alone. This approach may also help guide the development of future treatments.”

These statements emphasize the FDA’s rationale for extending the treatment indication based on the existing evidence and similarities between the disease presentations. They should not be interpreted as evidence that efficacy has been established to the same degree in every bladder cancer subgroup.

What the Researchers and Regulatory Evidence Showed

1. The indication now includes papillary-only disease

The expanded indication covers adults with high-grade papillary-only non–muscle-invasive bladder cancer that has not responded to prior BCG treatment.

The earlier indication described in the report covered adults with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The expansion is important because patients with papillary-only disease have a distinct tumor presentation and previously lacked a treatment specifically approved for this setting, according to the supplied report.

2. The FDA relied on existing evidence and disease similarities

The report states that evidence from patients with carcinoma in situ, combined with similarities between carcinoma in situ and high-grade papillary-only disease, supported the expanded indication.

Both disease presentations may carry substantial risks of recurrence or progression when BCG alone is no longer effective.

The supplied article does not identify the precise clinical trial, provide a trial identifier, or present response rates and follow-up data for the papillary-only population. Accordingly, a detailed numerical efficacy comparison cannot be made from this report alone.

3. Anktiva is administered with BCG

Anktiva is an interleukin-15 r  eceptor agonist delivered directly into the bladder through a catheter. It is used in combination with BCG as part of the approved treatment approach.

BCG remains an established initial therapy for high-risk non–muscle-invasive bladder cancer. The combination is relevant for patients whose disease has persisted or recurred despite BCG treatment.

The supplied report does not provide enough detail to quantify the independent contribution of Anktiva relative to BCG or to compare this combination directly with alternative treatments.

Treatment Administration and Safety

Administration

The report describes an initial schedule of once-weekly intravesical administration for 6 weeks. Decisions regarding subsequent treatment are guided by the patient’s cancer response.

Clinicians should consult the current FDA-approved prescribing information for the complete dosing schedule, treatment eligibility criteria, monitoring requirements, contraindications, warnings, and instructions for subsequent treatment.

Adverse effects and laboratory abnormalities

The supplied report lists the following adverse effects or laboratory abnormalities associated with treatment:

The article does not provide incidence percentages, severity distributions, or comparative adverse-event rates for the newly approved population. These effects should therefore be presented as reported potential adverse effects, not as estimates of how frequently each occurs.

Clinical Significance

An additional treatment option for a defined subgroup

The expanded indication gives clinicians an FDA-approved combination option specifically for adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer.

This is particularly relevant when disease persists or recurs despite BCG, because such patients require individualized discussions about further treatment options and the risks of recurrence or progression.

Importance of distinguishing bladder cancer subtypes

Carcinoma in situ and papillary-only tumors are different disease presentations. Treatment decisions should account for the patient’s specific pathology, prior treatment response, disease extent, and overall clinical circumstances.

The new indication is not a general approval for every form or stage of bladder cancer. It applies to the defined population described in the regulatory announcement.

Implications for shared decision-making

Clinicians should discuss the intended benefit of treatment, administration requirements, potential adverse effects, monitoring, and other relevant management options with eligible patients.

The supplied report does not provide sufficient comparative data to determine whether Anktiva plus BCG is superior to every available alternative in this newly covered subgroup.

Limitations and Important Evidence Gaps

This report summarizes an FDA approval update rather than a complete clinical trial publication. Several limitations should be considered.

1. No detailed trial design: The supplied article does not identify the specific trial design supporting the expanded indication. It is therefore not appropriate to label the report itself as a randomized controlled trial, cohort study, or meta-analysis.

2. No numerical efficacy data: Response rates, duration of response, recurrence-free survival, progression outcomes, and other quantitative efficacy measures are not supplied for the newly approved population.

3. Limited comparative evidence in the article: The report does not provide direct comparisons with other treatments for BCG-unresponsive papillary-only disease.

4. Incomplete safety statistics: Although several adverse effects and laboratory abnormalities are listed, their incidence, severity, and relationship to treatment are not quantified.

5. Regulatory rationale is summarized: The report describes evidence from carcinoma in situ and similarities with papillary-only disease but does not include the full FDA review or the detailed evidence supporting the decision.

6. No DOI or full original study citation: The supplied article does not identify a specific peer-reviewed publication or DOI for the evidence supporting the expanded indication.

For clinical decisions, the current FDA announcement and approved prescribing information should be consulted alongside the relevant clinical evidence.

What Doctors Should Know

• Confirm eligibility. The expanded indication described in the report is for adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer.

• Distinguish papillary-only disease from carcinoma in situ. The expanded indication specifically addresses patients with papillary-only disease.

• Understand the combination regimen. Anktiva is administered intravesically with BCG, not described in this report as a stand-alone replacement for BCG.

• Review the complete prescribing information. The report provides an initial weekly schedule for 6 weeks but not all treatment and monitoring details.

• Discuss potential adverse effects. Urinary symptoms, hematuria, urinary tract infections, fever, chills, musculoskeletal pain, and laboratory abnormalities are among the reported effects.

• Avoid overstating efficacy. The supplied article does not provide numerical response rates or comparative efficacy estimates for the newly approved subgroup.

• Individualize management. Treatment planning should take account of pathology, prior BCG response, disease extent, patient preferences, and appropriate specialist assessment.

Bottom Line

The FDA expanded Anktiva’s indication in combination with BCG to include adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer. The approval provides a specifically indicated treatment option for a subgroup previously distinct from the carcinoma-in-situ population covered by the earlier indication.

The treatment is administered directly into the bladder, with the initial schedule described as weekly for 6 weeks and subsequent decisions guided by cancer response. Potential adverse effects include urinary symptoms, hematuria, urinary tract infections, fever, chills, musculoskeletal pain, and elevated potassium or creatinine levels.

The supplied report does not provide detailed efficacy statistics for the new indication. Clinicians should consult the FDA-approved prescribing information and supporting clinical evidence when assessing treatment suitability and discussing benefits and risks with patients.

Original Research, FDA Announcement, and DOI

Regulatory update: FDA expansion of the indication for nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG.

Original clinical study: The supplied report does not specify a single original clinical study or provide a complete citation for the evidence underlying the expanded indication.

DOI: Not provided in the supplied article.

FDA official information: The FDA announcement and current prescribing information should be consulted to verify the precise approved indication, treatment schedule, safety information, and supporting evidence.

Editorial note: This educational summary is not a substitute for the official prescribing information or individualized medical advice.